Leadership Team

 

Meet Our Leadership Team

The leadership team at CrownBio has a deep understanding of the pharmaceutical industry, and significant experience in building and operating businesses and major departments within the top US Pharmaceutical’s R&D and preclinical programs. Our objective is to deliver fast, cost-effective preclinical research services for pharmaceutical, biotechnology, and medical device companies.

Jean-Pierre Wery, Ph.D.

CHIEF EXECUTIVE OFFICER

Prior to joining CrownBio, Dr. Wery was Chief Scientific Officer at Monarch Life Sciences, a company dedicated to the discovery and development of protein biomarkers. Prior to Monarch, Dr. Wery spent three years at Vitae Pharmaceuticals, Inc. where he was VP of Computational Drug Discovery. Before joining Vitae he worked for 12 years at Eli Lilly and Company in various scientific and management positions.

Dr. Wery received his B.S. and Ph.D. in Physics from the University of Liege, Belgium. Following his Ph.D., he completed postdoctoral studies at Purdue University with Prof. Jack Johnson. Dr. Wery has authored more than 50 abstracts and publications.


Eva Ho

CHIEF FINANCIAL OFFICER

Eva Ho is responsible for leading the company’s global finance organization and serves as a member of the company’s Executive Committee. Eva joined CrownBio in June 2016 as Chief Financial Officer.

Eva has extensive finance leadership experience at multinational corporations across several industries. Before joining CrownBio, she served as CFO for TWi Pharmaceuticals, CFO and Spokesperson for Acer Computer, and EVP and CFO for The Test Rite Group. Prior to that, she held senior finance positions with Sun Microsystems, Inc. and Oracle.

Eva holds an M.B.A. degree in accounting from the University of Denver, and a bachelor’s degree in Economics from National Taiwan University. Eva is a certified public accountant in the state of Colorado, USA.


Laurie Heilmann

PRESIDENT GLOBAL LIFE SCIENCE AND DIAGNOSTIC SOLUTIONS DIVISION


As President of CrownBio Global Life Science and Diagnostic Solutions Division, Laurie leads strategy development and is responsible for the commercialization of a unique portfolio of products and services that support clinical and diagnostic across several therapeutic concentrations, including oncology, inflammation, cardiovascular, metabolic and neurological diseases.

Laurie brings more than 30 years of executive leadership experience and an exceptional track record in the development of new business channels and global marketing strategies within the life sciences industry. Heilmann has led initiatives in biotech, drug development, medical devices, and health care technologies across diverse therapeutic backgrounds including oncology, CNS and CVMD.

Prior to this Laurie held the role of, Chief Business Officer (CBO) at CrownBio, she aligned sales, marketing and R&D to synergize strategic initiatives and guide company expansion, including leading the selection and integration of CrownBio’s recent acquisitions. Heilmann’s efforts have helped transform CrownBio into a prominent global player in the pre-clinical oncology and CVMD service markets and have consistently driven 35% growth throughout her tenure.

Heilmann's synthesis of business, clinical research, and technological acumen is ideal for assessing needs and assembling strategically sound, high-value solutions for CrownBio's clients. Her multifaceted experience from concept to commercialization, and knowledge of FDA and sponsor requirements in the US, Europe, India, and Asia, is vital to CrownBio's strategic global growth, as well as its expansion in the preclinical services market. She is an active member of numerous industry organizations.


Dr. Yangzhou Wang (王泱洲)

Chief Operations Officer

In his current role, Dr. Wang has the overall responsibilities to ensure top-flight operations at various Crown sites across the globe. He formerly served as a Vice President of International Sales and Business Development for WuXi AppTec, where he has the P&L responsibilities for WuXi’s international testing business, and where he built and led a team of sales, marketing, and technical sales professionals. Prior to that, he was an M&A/integration and corporate business development leader at Life Technologies/Applied Biosystems, responsible for integrating a cancer genomics informatics company and for developing/managing a global network of academic centers and pharma companies to advance cancer diagnostics using genomic technology. And before Life Tech, he was a manager at the Hewlett Packard Laboratories and an assistant professor at the Hauptman Woodward Medical Institute/SUNY Buffalo. Dr. Wang holds a Ph.D. in Cellular Molecular Biology from Roswell Park Cancer Institute and an M.Eng. in computer sciences from University of Colorado at Boulder.


Yixin (Jim) Wang, M.D.

SENIOR VICE PRESIDENT CARDIOVASCULAR AND METABOLIC DISEASES (CVMD) RESEARCH; PRESIDENT OF Crown Bioscience Indianapolis (CBIN) and Louisiana (CBLA), Inc.

Dr. Wang started his academic career as a postdoctoral researcher at Boston University in 1987. In 1992 he became an assistant professor at the University of Tennessee in Memphis where he worked until 1996. He has worked in several major Pharma (GSK, Roche, Schering/Bayer AG) as a Scientist, Senior Scientist, and Principle Scientist from 1990 to 2008 and in a start-up biotech (Arete Therapeutics, Inc.) as a Director of Pharmacology from 2008 to 2009.

In 2010, he joined CrownBio as the Head of CVMD Research. SENIOR VP CARDIOVASCULAR AND METABOLIC DISEASES (CVMD) RESEARCH; PRESIDENT OF Crown Bioscience Indianapolis (CBIN) and Louisiana (CBLA), Inc. He has authored nearly 100 publications between research articles, invited reviewers, and book chapters, and has submitted patent applications in the areas of diabetes and metabolic diseases, heart and renal failure, hypertension, thrombosis, hemophilia, atherosclerosis and dyslipidemia, hemodynamics, pharmacokinetics and pharmacodynamics, safety pharmacology, etc. He has been involved in all stages of pharmaceutical R&D, from early stage target discovery and validation, to compound (large and small molecules) discovery, selection and profiling, IND filing, and clinical trials in Phase I & II.


Henry Li, Ph.D.

SENIOR VICE PRESIDENT OF GLOBAL SCIENTIFIC RESEARCH AND INNOVATIONS (SRI)

Henry QX Li, PhD leads CrownBio's Global Scientific Research and Innovation Division, focused on accelerating the creation of new, innovative products and services for discovery and translational sciences. Prior to this, Dr. Li successfully led and expanded CrownBio’s patient-derived xenograft (PDX) based Translational Oncology platform (2011-2016), and led the Biomarker and Diagnostic Technologies Division developing novel proprietary translational technologies for precise cancer diagnosis, predictive biomarker discovery, immuno-oncology biomarker detection and quantification, as well as rare cell identification and characterization (2016-2018).

Before joining CrownBio, Dr. Li has over 20 years of biopharmaceutical, as well as academic R&D, experience in cancer and viral infection, including leadership roles as R&D Director/Senior Director in several US-based biotech companies. Dr. Li currently holds visiting Professor position at Peking University-State Key Laboratory.

Dr. Li earned his Ph.D. in Molecular Biology/Biochemistry from the University of California (Irvine) and completed his postdoctoral training at UCLA School of Medicine. He has published more than 60 manuscripts and edited 3 books in the biopharmaceutical areas. He is also on the editorial board of Current Signal Transduction Therapy.


Leon Hall Ph.D.

VICE PRESIDENT OF GLOBAL SCIENTIFIC EXCELLENCE

Dr. Hall previously served as Crown Bioscience’s Senior Scientific Director and led Crown Bioscience’s Global Scientific Excellence Initiative. Dr. Hall established the Global Quality Council as well as the Global Scientific Councils that govern Crown Bioscience’s research in oncology, immunology, inflammation, cardiovascular and metabolic diseases. His efforts have ensured global standards of excellence, harmonization and fostered collaborations in scientific innovation and R&D.

Leon holds a Ph.D. from the University of Leicester, England, in Molecular Pathology and Toxicology. He has over 15 years of preclinical rodent research experience and is considered an industry leader in the application of humanized mouse models in immunology and immuno-oncology.


Michael Prosser

VICE PRESIDENT CORPORATE DEVELOPMENT AND STRATEGY

Michael Prosser leads CrownBio’s Corporate Development and Strategy department, leveraging extensive experience in contract research and international pharmaceutical drug development. Prior to this Michael oversaw the establishment of CrownBio’s initial presence and growth in Europe, before taking on the general management of CrownBio’s sites in both the UK and San Diego, USA, leading the integration of both acquired subsidiaries.

Prior to joining CrownBio, Michael held a number of roles building global business development and product management teams. This includes with Accelera (the preclinical CRO of Nerviano Medical Sciences), MDS Pharma Services, and SNBL USA, Ltd. Michael also managed the International Affairs group at SNBL USA’s parent company, Shin Nippon Biomedical Laboratories (SNBL) in Kagoshima, Japan, and worked as a bench scientist at Eisai Pharmaceuticals in London.

Michael earned an M.Sc. in Applied Molecular Biology and Biotechnology from University College London, and a B.Sc. degree in Pharmacology from the University of Dundee.